The record is publicly accessible, but files are restricted to users with access.
If you would like to request access to these files, please fill out the form below.
The source code is available for non-profit, academic research purposes only. Following the policy of NIH/NCI, the requesters should fill in, sign, and return the following software use agreement. The Recipient Investigator is most likely not the Authorized Recipient Official. An Authorized Recipient Official is someone who is authorized to sign legal documents on behalf of the institution; this person usually works in the Technology Transfer Department or the Office of Sponsored Research. The Authorized Recipient Official’s signature is legally binding upon the institution and they regularly sign contracts or research agreements. This software use agreement may also require review from your institution’s legal team.
We recommend the requesters to copy the following contents into a word processor, insert the specific research question to be addressed with the CODEFACS and LIRICS code, generate a PDF document with the requester's requisite signatures, and send it to Kevin Chang (changke@mail.nih.gov) along with Zenodo request. (Unfortunately, Zenodo does not have the option for us to provide the requesters with a Word document version of the software use agreement). If you have any questions, feel free to contact us.
====================================================================================================
SOFTWARE TRANSFER AGREEMENT
PROVIDER: National Cancer Institute (NCI)
RECIPIENT: _________________________________________
WHEREAS, PROVIDER has certain proprietary software and associated material described below
(hereinafter, collectively referred to as “Software”)
National Cancer Institute COnfident DEconvolution For All Cell Subsets (CODEFACS) and Ligand Receptor Interactions between Cell Subsets (LIRICS) software (NIH Ref. No. E-044-2020), provided as source codes (written in R) for two computer programs, i) CODEFACS: which estimates both cell type abundance and mean cell type gene expression levels in each sample and ii) LIRICS: which predicts ligand-receptor interactions that are likely to occur in specific patient sub-populations based on deconvolved expression from CODEFACS and a literature curated immunological database included within, as described in Wang, Patkar et al. (Cancer Discovery 2022, DOI: 10.1158/2159-8290.CD-21-0887), including further improvements thereof, and related documentation.
PROVIDER agrees to transfer such Software to RECIPIENT, to be used solely in connection
with the following research activity and for the following reasons (hereinafter “Project”). Describe
with specificity the scope of use of Software under this Agreement:
_____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
NOW, THEREFORE, in consideration of the premises and mutual covenants contained herein, the
PROVIDER and RECIPIENT agree, and RECIPIENT SCIENTIST acknowledges as follows:
1. SOFTWARE SHALL NOT BE USED FOR TREATING OR DIAGNOSING HUMAN
SUBJECTS.
2. RECIPIENT will not license or sell or use Software for commercial purposes or applications.
RECIPIENT shall retain control over Software and further will not transfer the
Software to individuals not under RECIPIENT SCIENTIST’s direct supervision without the
advance written approval of PROVIDER. RECIPIENT agrees to comply with all regulations
applicable to the Project and the use of the Software.
3. RECIPIENT agrees not to copy Software, in whole or in part, except as required for use by
RECIPIENT SCIENTIST for the conduct of the Project. RECIPIENT shall not modify, extend,
decompile, make derivatives of or reverse engineer the Software without written permission
from PROVIDER.
4. In all oral presentations or written publications concerning the Project, RECIPIENT will
acknowledge PROVIDER’s contribution of SOFTWARE unless requested otherwise. RECIPIENT may
publish or otherwise publicly disclose the results of the Project.
5. Title in the Software shall remain with the PROVIDER. It is understood that nothing herein shall
be deemed to constitute, by implication or otherwise, the grant to either party by the other of
any license or other rights under any patent, patent application or other intellectual property
right or interest. PROVIDER reserves the right to distribute Software to others and to use it for PROVIDER’s own purposes.
6. When the Project is completed or this Agreement is terminated, whichever occurs first,
RECIPIENT will destroy all copies of Software unless directed otherwise by PROVIDER in writing.
7. This Agreement may be terminated by either RECIPIENT or PROVIDER by providing 30 days
advance notice.
8. The PROVIDER and RECIPIENT each shall retain title to any patent or other intellectual property of
their respective employees developed or created in the course of the Project defined in this
Agreement. Neither PROVIDER nor RECIPIENT promise rights in advance for inventions developed
under this Agreement.
9. No indemnification for any loss, claim, damage, or liability is intended or provided by any
party under this Agreement. Each party shall be liable for any loss, claim, damage, or liability
that said party incurs as a result of said party’s activities under this Agreement, except that the
NCI, as an agency of the United States, assumes liability only to the extent as provided under
the United States Federal Tort Claims Act (28 U.S.C. Chapter 171).
10. Software is supplied AS IS, without any accompanying services or improvements from
PROVIDER. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES,
EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE. PROVIDER makes no representations that the use
of Software will not infringe any patent or proprietary rights of third parties.
PROVIDER INFORMATION and AUTHORIZED SIGNATURE:
Provider Scientist: Eytan Ruppin, M.D.
Provider Organization: National Cancer Institute
Address: 9609 Medical Ctr. Dr., RM 1E530, Rockville, MD 20850
Name of Authorized Official:
Title of Authorized Official:
_________________________________ __________________
Signature of Authorized Official Date
RECIPIENT INFORMATION and AUTHORIZED SIGNATURE:
Recipient Scientist: _______________________________________________________
Recipient Organization: ___________________________________________________
Address: _______________________________________________________________
Name of Authorized Official: _______________________________________________
Title of Authorized Official: _________________________________________________
_________________________________ __________________
Signature of Authorized Official Date
Certification of Recipient Scientist: I have read and understood the conditions outlined in this Agreement, and I understand that I must abide by them to receive and use the Software.
__________________________________ ________________
Recipient Scientist Date